GSK461364, another ATP-competitive and selective PLK1 inhibitor, demonstrated antiproliferative activity across multiple tumor cell lines, though it also caused anemia and other blood disorders in clinical trials (Chou et al., 2016). Here, PLK1 is linked to anemia (phenotype).